US9539218 — Prevention and treatment of thromboembolic disorders
Method of Use · Assigned to Bayer Intellectual Property GmbH · Expires 2034-02-17 · 8y remaining
What this patent protects
This patent protects a method of treating thromboembolic disorders by administering a direct factor Xa inhibitor once daily in oral form.
USPTO Abstract
The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.
Drugs covered by this patent
- Xarelto (rivaroxaban) · Johnson & Johnson
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1955 |
— | Xarelto |
U-1957 |
— | Xarelto |
U-1953 |
— | Xarelto |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.